ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9825
0.23%
Brent Oil
83.61
0.08%
Bitcoin
59,305.23
1.83%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aclaris Therapeutics Inc (ACRS)

  7. Aclaris Therapeutics Inc (ACRS) Noticias

ACRS Aclaris Therapeutics Inc

1.30
0.04 (3.17%)
Fuera de horario
Última actualización: 16:01:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aclaris Therapeutics Inc ACRS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.04 3.17% 1.30 16:01:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.25 1.21 1.31 1.31 1.26
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202406:00GLOBEAclaris Therapeutics to Announce First Quarter 2024..
23/4/202407:00PRNUSFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C)..
05/3/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202406:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202406:14EDGAR2Form 8-K - Current report
27/2/202406:00GLOBEAclaris Therapeutics Reports Fourth Quarter and Full Year..
14/2/202419:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202413:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202413:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202418:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:31EDGAR2Form 8-K/A - Current report: [Amend]
05/2/202415:30EDGAR2Form 8-K - Current report
19/1/202406:30EDGAR2Form 8-K - Current report
16/1/202406:00GLOBEAclaris Therapeutics Announces Leadership Changes and..
10/1/202406:00GLOBEAclaris Therapeutics Announces Top-line Results from 4-Week..
03/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:15EDGAR2Form 8-K - Current report
19/12/202315:01GLOBEAclaris Therapeutics Provides Corporate Update
05/12/202315:01GLOBEAclaris Therapeutics Announces Patent License Agreement with..
13/11/202306:42EDGAR2Form 8-K - Current report
13/11/202306:00GLOBEAclaris Therapeutics Announces Top-line Results from 12-Week..
06/11/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202306:15EDGAR2Form 8-K - Current report
06/11/202306:00GLOBEAclaris Therapeutics Reports Third Quarter 2023 Financial..
25/10/202315:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202315:06EDGAR2Form 144 - Report of proposed sale of securities
03/10/202306:00GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
20/9/202306:00GLOBEAclaris Therapeutics to Participate in the 2023 Cantor..
18/9/202307:00EDGAR2Form 8-K - Current report
18/9/202306:00GLOBEAclaris Therapeutics Announces Positive Results from Phase 1..
07/9/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202316:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202315:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202315:20EDGAR2Form 144 - Report of proposed sale of securities
07/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202306:15EDGAR2Form 8-K - Current report
07/8/202306:00GLOBEAclaris Therapeutics Reports Second Quarter 2023 Financial..
03/8/202315:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202315:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202306:01GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
02/6/202306:00GLOBEAclaris Therapeutics to Participate in Two June Healthcare..
08/5/202306:00GLOBEAclaris Therapeutics Reports First Quarter 2023 Financial..

Su Consulta Reciente

NASDAQ
ACRS
Aclaris Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados